Nov 2 (Reuters) – Teva Pharmaceutical Industries Limited : * TEVA TO DISCONTINUE PHASE 2 TOPAS-MSA STUDY OF EMRUSOLMIN (TEV-‘286) FOLLOWING INTERIM FUTILITY ANALYSIS * TEVA – DECISION BASED ON INTERIM
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Nov 2 (Reuters) - Ta Yang Group Holdings Ltd: * ENTERS SETTLEMENT AGREEMENT ON WINDING-UP…
Nov 2 (Reuters) - Versant's MS NOW said on Monday it was expanding its direct-to-consumer…
By Curtis Williams HOUSTON, Nov 2 (Reuters) - Natural gas deliveries to two of the…
VIDEO SHOWS: PRESS CONFERENCE COMMENTS FROM MANCHESTER UNITED HEAD COACH MICHAEL CARRICK AND MIDFIELDER KOBBIE…
By Stefano Rebaudo Nov 2 (Reuters) - Global stocks were headed for gains on Monday…
(Updates with US open, release of ISM manufacturing data, added comment) * Stocks higher following…